Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide a promising additional treatment option for selected patients with peritoneal carcinomatosis arising from colorectal cancer. Due to the aggressive surgery the concept is associated with a significant morbidity rate. Thus, the operative risk has to be evaluated against the background of the expected improvement of the oncological outcome.
(c) 2009 Wiley-Liss, Inc.